ArticleFrontiers in immunology2018

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

Lisa A King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.